Brief: Mithra CDMO Announces Collaboration With MedinCell For Development Of Injectable Products For Malaria And Transplant Rejection

Medincell SA

26/04/2022 06:35

April 26 (Reuters) - MITHRA PHARMACEUTICALS SA  MITRA.BR :
    * MITHRA CDMO ANNOUNCES COLLABORATION WITH MEDINCELL FOR
DEVELOPMENT OF INJECTABLE PRODUCTS FOR MALARIA AND TRANSPLANT
REJECTION
    * COLLABORATION FOR DEVELOPMENT OF LONG-ACTING INJECTABLE
INNOVATIVE PRODUCTS TO ADDRESS MAJOR GLOBAL HEALTHCARE
CHALLENGES
    * TWO MEDINCELL'S PRODUCT CANDIDATES IN SCOPE OF
COLLABORATION:
    * A 3-MONTH LONG ACTING INJECTABLE DESIGNED AS AN ADDITIONAL
TOOL
TO FIGHT MALARIA, ONE OF MAIN HEALTH THREATS WORLDWIDE WITH MORE
THAN 200 MILLION PEOPLE INFECTED YEARLY
    * A LONG-ACTING INJECTABLE OF TACROLIMUS FOR TRANSPLANT
PATIENTS
AIMING AT IMPROVING EFFICACITY, TOLERANCE AND PATIENT OBSERVANCE
    * PROJECTS THAT PERFECTLY COMBINE MITHRA CDMO'S CORE
ACTIVITIES: A
BROAD EXPERIENCE IN COMPLEX THERAPEUTIC POLYMERIC FORMS AND A
SPECIFIC KNOW-HOW IN FLEXIBLE COMPLEX LIQUID INJECTABLES

Source text for Eikon:  ID:nNDL40Tj9y 
Further company coverage:  MITRA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))